Cargando…

Alimam S, Villiers W, Dillon R, et al. Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Adv. 2021;5(4):1059-1068.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267109/ https://www.ncbi.nlm.nih.gov/pubmed/34137812 http://dx.doi.org/10.1182/bloodadvances.2021005271

Ejemplares similares

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
por: Ji, Liying, et al.
Publicado: (2017)

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia
por: Vu, Hoang Anh, et al.
Publicado: (2019)

Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia
por: Lim, Ken-Hong, et al.
Publicado: (2017)

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia
por: Kang, Min-Gu, et al.
Publicado: (2016)

Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis
por: Lim, K-H, et al.
Publicado: (2015)

James Dillon.
por: Dillon, James
Publicado: (1995)

Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111.
Publicado: (2022)

Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia
por: Gadomska, Grażyna, et al.
Publicado: (2018)

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
por: Kubuki, Yoko, et al.
Publicado: (2017)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Jenny Villiers : una historia de teatro
por: Priestley, J. B. (John Boynton), 1894-1984
Publicado: (1949)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia
por: Langabeer, Stephen E., et al.
Publicado: (2016)

Splenic mass in a case of CALR‐mutated essential thrombocythemia
por: Imashuku, Shinsaku, et al.
Publicado: (2018)

Retinal neovascularization in the setting of CALR-mutation positive essential thrombocythemia
por: Heydinger, Stanton P, et al.
Publicado: (2023)

Chronic urticaria reveals JAK2V617F positive essential thrombocythemia
por: Albanesi, Marcello, et al.
Publicado: (2021)

Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter
por: Trifa, Adrian P., et al.
Publicado: (2014)

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
por: Belcic Mikic, Tanja, et al.
Publicado: (2019)

Invasive ductal breast carcinoma preceded by CALR‐positive essential thrombocythemia
por: Ali, Elrazi A., et al.
Publicado: (2021)

Dr Richard de Villiers – a tribute
por: Koenig, Jean-Claude
Publicado: (2022)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Singdong, Roongrudee, et al.
Publicado: (2016)

JAK2V617F阳性转CALR基因突变阳性血小板增多症一例
Publicado: (2017)

Oral squamous cell carcinoma with essential thrombocythemia and positive JAK2 (V617F) mutation
por: Rahman, Kurnia H., et al.
Publicado: (2021)

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia
por: Abdelghani, Maroua, et al.
Publicado: (2022)

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2023)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
por: Yönal, İpek, et al.
Publicado: (2016)

Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2(V617F)-positive Essential Thrombocythemia
por: Chen, Wei-Bi, et al.
Publicado: (2018)

Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report
por: Sobas, M. A., et al.
Publicado: (2017)

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
por: Silver, Richard T., et al.
Publicado: (2019)

Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review
por: Chen, Rong, et al.
Publicado: (2022)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
por: Zulkeflee, Razan Hayati, et al.
Publicado: (2021)

Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms
por: Wiriyaukaradecha, Kriangpol, et al.
Publicado: (2022)

NGC 1068 Workshop
por: Gallimore,, et al.
Publicado: (1996)

Lung Clear “Sugar” Cell Tumor and JAK V617F Positive Essential Thrombocythemia: a Simple Coincidence?
por: Yazak, Volkan, et al.
Publicado: (2013)

JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia: A case report
por: Oda, Yasuhiro, et al.
Publicado: (2019)

A case of ischemic stroke with hemorrhagic transformation associated with essential thrombocythemia and JAK-2 V617F mutation
por: Yan, Ran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rii3j05hea2f75r3jf6nucu15n